482 related articles for article (PubMed ID: 25178252)
21. Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban.
Mousa SA
Methods Mol Biol; 2010; 663():181-201. PubMed ID: 20617418
[TBL] [Abstract][Full Text] [Related]
22. Rivaroxaban: an oral direct inhibitor of factor Xa.
Gulseth MP; Michaud J; Nutescu EA
Am J Health Syst Pharm; 2008 Aug; 65(16):1520-9. PubMed ID: 18693206
[TBL] [Abstract][Full Text] [Related]
23. Rivaroxaban, an oral direct factor Xa inhibitor.
Piccini JP; Patel MR; Mahaffey KW; Fox KA; Califf RM
Expert Opin Investig Drugs; 2008 Jun; 17(6):925-37. PubMed ID: 18491993
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
Hellwig T; Gulseth M
Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
[TBL] [Abstract][Full Text] [Related]
25. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
26. [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].
Ordovás Baines JP; Climent Grana E; Jover Botella A; Valero García I
Farm Hosp; 2009; 33(3):125-33. PubMed ID: 19712596
[TBL] [Abstract][Full Text] [Related]
27. Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery.
Turpie AG; Schmidt AC; Kreutz R; Lassen MR; Jamal W; Mantovani L; Haas S
Vasc Health Risk Manag; 2012; 8():363-70. PubMed ID: 22701330
[TBL] [Abstract][Full Text] [Related]
28. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
Akwaa F; Spyropoulos AC
Hosp Pract (1995); 2013 Feb; 41(1):8-18. PubMed ID: 23466963
[TBL] [Abstract][Full Text] [Related]
29. [Rivaroxaban (Xarelto): efficacy and safety].
Rosencher N; Arnaout L; Chabbouh T; Bellamy L
Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S22-7. PubMed ID: 19185784
[TBL] [Abstract][Full Text] [Related]
30. [Rivaroxaban (Xarelto): new anticoagulant inhibitor of factor Xa].
Scheen AJ
Rev Med Liege; 2009 Oct; 64(10):538-43. PubMed ID: 19911670
[TBL] [Abstract][Full Text] [Related]
31. Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.
Martínez-Rubio A; Dan GA; Kaski JC
Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):933-47. PubMed ID: 24948333
[TBL] [Abstract][Full Text] [Related]
32. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
[TBL] [Abstract][Full Text] [Related]
33. A cost-analysis model for anticoagulant treatment in the hospital setting.
Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
[TBL] [Abstract][Full Text] [Related]
34. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Laux V; Perzborn E; Kubitza D; Misselwitz F
Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
[TBL] [Abstract][Full Text] [Related]
35. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
Cohen AT; Dobromirski M
Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
[TBL] [Abstract][Full Text] [Related]
36. Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism.
Yong CM; Boyle AJ
Curr Vasc Pharmacol; 2010 Jan; 8(1):5-11. PubMed ID: 19485937
[TBL] [Abstract][Full Text] [Related]
37. XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.
Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; van Eickels M; Turpie AG
Vasc Health Risk Manag; 2014; 10():425-34. PubMed ID: 25083135
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).
Sherwood MW; Douketis JD; Patel MR; Piccini JP; Hellkamp AS; Lokhnygina Y; Spyropoulos AC; Hankey GJ; Singer DE; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Becker RC;
Circulation; 2014 May; 129(18):1850-9. PubMed ID: 24552831
[TBL] [Abstract][Full Text] [Related]
39. Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation.
Tanigawa T; Kaneko M; Hashizume K; Kajikawa M; Ueda H; Tajiri M; Paolini JF; Mueck W
Drug Metab Pharmacokinet; 2013; 28(1):59-70. PubMed ID: 22813718
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]